ATE237337T1 - Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) - Google Patents
Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna)Info
- Publication number
- ATE237337T1 ATE237337T1 AT95939282T AT95939282T ATE237337T1 AT E237337 T1 ATE237337 T1 AT E237337T1 AT 95939282 T AT95939282 T AT 95939282T AT 95939282 T AT95939282 T AT 95939282T AT E237337 T1 ATE237337 T1 AT E237337T1
- Authority
- AT
- Austria
- Prior art keywords
- dithio
- bis
- cisplatin
- dimesna
- ethanesulfonate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title abstract 2
- 229960004316 cisplatin Drugs 0.000 title abstract 2
- 229950009278 dimesna Drugs 0.000 title 1
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 title 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 title 1
- SDNJNDFHCODQDQ-UHFFFAOYSA-N n-(2-ethylphenyl)-2-[[2-[(2-ethylphenyl)carbamoyl]phenyl]disulfanyl]benzamide Chemical compound CCC1=CC=CC=C1NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(=O)NC1=CC=CC=C1CC SDNJNDFHCODQDQ-UHFFFAOYSA-N 0.000 title 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/338,379 US5789000A (en) | 1994-11-14 | 1994-11-14 | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| PCT/EP1995/004490 WO1996014852A1 (en) | 1994-11-14 | 1995-11-14 | Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE237337T1 true ATE237337T1 (de) | 2003-05-15 |
Family
ID=23324592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95939282T ATE237337T1 (de) | 1994-11-14 | 1995-11-14 | Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US5789000A (de) |
| EP (1) | EP0792154B1 (de) |
| JP (3) | JP4171526B2 (de) |
| KR (1) | KR100411380B1 (de) |
| CN (2) | CN1165483B (de) |
| AT (1) | ATE237337T1 (de) |
| AU (1) | AU706181B2 (de) |
| CA (1) | CA2202170C (de) |
| DE (1) | DE69530412T2 (de) |
| DK (1) | DK0792154T3 (de) |
| ES (1) | ES2191717T3 (de) |
| PT (1) | PT792154E (de) |
| WO (1) | WO1996014852A1 (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6037336A (en) * | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| CN1129432C (zh) * | 1996-09-23 | 2003-12-03 | 比奥纽默里克药物公司 | 采用二硫醚降低碳铂的毒性作用 |
| US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| RU2144374C1 (ru) * | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
| US20070142267A1 (en) * | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| US6197831B1 (en) * | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US6034126A (en) * | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6156350A (en) * | 1999-12-02 | 2000-12-05 | Corazon Technologies, Inc. | Methods and kits for use in preventing restenosis |
| WO2001080832A2 (en) | 2000-04-26 | 2001-11-01 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| AU2877202A (en) * | 2000-11-02 | 2002-05-15 | Sloan Kettering Inst Cancer | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| US6540733B2 (en) * | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
| WO2002056755A2 (en) * | 2001-01-19 | 2002-07-25 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer |
| CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| KR20040049830A (ko) * | 2001-07-09 | 2004-06-12 | 애프톤 코포레이션 | 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방 |
| US6352979B1 (en) * | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
| PL370867A1 (en) * | 2001-09-24 | 2005-05-30 | Tosk, Inc. | Reduced toxicity cisplatin formulations and methods for using the same |
| US7176192B2 (en) * | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
| US6596320B1 (en) * | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
| CA2480045C (en) * | 2002-03-28 | 2013-09-24 | Medical College Of Ohio | Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20040014730A1 (en) * | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
| MXPA05006721A (es) * | 2002-12-21 | 2005-09-30 | Bionumerik Pharmaceuticals Inc | Metodo para tratamiento de pacientes expuestos a agentes quimicos toxicos. |
| US7714139B2 (en) * | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| JP4936898B2 (ja) * | 2003-12-17 | 2012-05-23 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | ジスルフィド類の合成方法 |
| AU2005228897B2 (en) * | 2004-03-29 | 2009-12-10 | Cancer Advances, Inc. | Monoclonal antibodies to gastrin hormone |
| US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| US20050256055A1 (en) * | 2004-05-12 | 2005-11-17 | Hausheer Frederick H | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| US7235589B2 (en) | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
| US20060063742A1 (en) * | 2004-09-21 | 2006-03-23 | Hausheer Frederick H | Method of treatment for or protection against lymphedema |
| US7282602B2 (en) * | 2004-09-21 | 2007-10-16 | Bionumerik Pharmaceuticals, Inc. | Medicinal disulfide salts |
| JP2008513536A (ja) | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| CN100443081C (zh) * | 2005-04-05 | 2008-12-17 | 吴一心 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
| AU2006320162B2 (en) * | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| DK1991237T3 (en) * | 2005-12-13 | 2015-04-27 | Bionumerik Pharmaceuticals Inc | Chemoprotective methods and compositions |
| US20070219268A1 (en) * | 2006-03-16 | 2007-09-20 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
| WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| RU2009133447A (ru) * | 2007-02-09 | 2011-03-20 | Пониард Фармасьютикалз, Инк. (Us) | Дозированная форма пикоплатина |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| JP2010533714A (ja) * | 2007-07-16 | 2010-10-28 | ポニアード ファーマシューティカルズ， インコーポレイテッド | ピコプラチンのための経口製剤 |
| WO2009039190A1 (en) * | 2007-09-17 | 2009-03-26 | Gene Express, Inc. | Cancer risk biomarker |
| US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
| WO2009067690A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for safe and effective treatment using oxazaphosphorine drugs |
| AU2009210656A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
| US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| CN102014891B (zh) | 2008-03-14 | 2013-12-18 | 比奥纽默里克药物公司 | 增加癌症患者存活时间的化合物的组合物和使用方法 |
| EP2252246B1 (de) * | 2008-03-14 | 2014-06-18 | Bionumerik Pharmaceuticals, Inc. | Chemoprotektive verfahren und zusammensetzungen |
| EP2249825B1 (de) * | 2008-03-14 | 2015-10-07 | Bionumerik Pharmaceuticals, Inc. | Behandlungsverfahren und zusammensetzungen gegen lungenkrebs, adenokarzinom und andere medizinische krankheitszustände |
| US20110064828A1 (en) * | 2009-09-11 | 2011-03-17 | Novelos Therapeutics, Incorporated | Treatment of metastatic tumors and other conditions |
| TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前－乳劑調配物及其製造與使用之方法 |
| SG185389A1 (en) | 2010-05-03 | 2012-12-28 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| EP2804602B1 (de) * | 2012-01-20 | 2024-12-04 | Del Mar Pharmaceuticals | Verwendung von substituierten hexitolen mit dianhydrogalactitol und analoga zur behandlung von neoplastischen erkrankungen und krebsstammzellen einschliesslich glioblastoma multforme und medulloblastoma |
| MX2015000810A (es) * | 2012-07-19 | 2015-06-05 | Relypsa Inc | Composiciones que comprenden polímeros reticulados con enlace a cationes. |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| JP7469225B2 (ja) | 2017-06-15 | 2024-04-16 | キャンサー アドヴァンシーズ インク． | 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法 |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2806866C3 (de) * | 1978-02-17 | 1981-02-12 | Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld | Verwendung von Salzen von Dithiodialkansulfonsäuren |
| US4310515A (en) * | 1978-05-30 | 1982-01-12 | Bristol-Myers Company | Pharmaceutical compositions of cisplatin |
| DE58900183D1 (de) * | 1988-03-19 | 1991-08-29 | Asta Pharma Ag | Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung. |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| JP3954115B2 (ja) * | 1992-07-28 | 2007-08-08 | アストラゼネカ・アクチエボラーグ | 注射剤および注射剤キット |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
-
1994
- 1994-11-14 US US08/338,379 patent/US5789000A/en not_active Expired - Lifetime
-
1995
- 1995-11-03 US US08/553,005 patent/US5902610A/en not_active Expired - Lifetime
- 1995-11-14 JP JP51574596A patent/JP4171526B2/ja not_active Expired - Fee Related
- 1995-11-14 DK DK95939282T patent/DK0792154T3/da active
- 1995-11-14 KR KR1019970703171A patent/KR100411380B1/ko not_active Expired - Lifetime
- 1995-11-14 CN CN951962310A patent/CN1165483B/zh not_active Expired - Lifetime
- 1995-11-14 AU AU41168/96A patent/AU706181B2/en not_active Expired
- 1995-11-14 DE DE69530412T patent/DE69530412T2/de not_active Expired - Lifetime
- 1995-11-14 ES ES95939282T patent/ES2191717T3/es not_active Expired - Lifetime
- 1995-11-14 EP EP95939282A patent/EP0792154B1/de not_active Expired - Lifetime
- 1995-11-14 CN CN2010102328968A patent/CN101987111A/zh active Pending
- 1995-11-14 PT PT95939282T patent/PT792154E/pt unknown
- 1995-11-14 WO PCT/EP1995/004490 patent/WO1996014852A1/en not_active Ceased
- 1995-11-14 CA CA002202170A patent/CA2202170C/en not_active Expired - Lifetime
- 1995-11-14 AT AT95939282T patent/ATE237337T1/de active
-
1997
- 1997-04-18 US US08/844,544 patent/US5866617A/en not_active Expired - Lifetime
- 1997-04-30 US US08/848,361 patent/US5866615A/en not_active Expired - Lifetime
- 1997-06-18 US US08/878,244 patent/US5866169A/en not_active Expired - Lifetime
-
2008
- 2008-02-28 JP JP2008047977A patent/JP2008133304A/ja active Pending
-
2012
- 2012-08-02 JP JP2012172119A patent/JP2012211198A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2202170C (en) | 2007-04-10 |
| CA2202170A1 (en) | 1996-05-23 |
| US5866615A (en) | 1999-02-02 |
| US5866617A (en) | 1999-02-02 |
| WO1996014852A1 (en) | 1996-05-23 |
| KR100411380B1 (ko) | 2004-04-30 |
| CN101987111A (zh) | 2011-03-23 |
| CN1165483B (zh) | 2012-09-05 |
| AU706181B2 (en) | 1999-06-10 |
| MX9703460A (es) | 1997-07-31 |
| DE69530412T2 (de) | 2003-10-30 |
| EP0792154A1 (de) | 1997-09-03 |
| ES2191717T3 (es) | 2003-09-16 |
| DE69530412D1 (de) | 2003-05-22 |
| PT792154E (pt) | 2003-09-30 |
| US5902610A (en) | 1999-05-11 |
| JP2012211198A (ja) | 2012-11-01 |
| JPH10509143A (ja) | 1998-09-08 |
| EP0792154B1 (de) | 2003-04-16 |
| AU4116896A (en) | 1996-06-06 |
| JP4171526B2 (ja) | 2008-10-22 |
| CN1165483A (zh) | 1997-11-19 |
| KR970706830A (ko) | 1997-12-01 |
| US5866169A (en) | 1999-02-02 |
| JP2008133304A (ja) | 2008-06-12 |
| DK0792154T3 (da) | 2003-08-04 |
| US5789000A (en) | 1998-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE237337T1 (de) | Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna) | |
| GR3017282T3 (en) | Novel arylpyridazines, their manufacture, use and medicaments containing them. | |
| ATE146674T1 (de) | Pharmazeutische zusammensetzung zur rektalen verabreichung von wirkstoffen mit topischer medizinischer wirkung im dickdarmniveau | |
| DE68917908D1 (de) | 4,4'-bis(methacryloylthio)diphenylsulfid und vernetzbare zusammensetzung daraus. | |
| DE3363270D1 (en) | Solubilized platinum(ii) complexes | |
| AU4484989A (en) | Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents | |
| GR3003068T3 (en) | (2,2-bis(aminomethyl)-1,3-propanediol-n,n')platinum complexes | |
| IT1230145B (it) | Complessi di rutenio (iii) come agenti antineoplastici. | |
| DK97085D0 (da) | Hidtil ukendte antineoplastiske platin(iv)-komplekser | |
| ATE25238T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von entzuendungen oder arthritis. | |
| GB2228679B (en) | Biocidal compositions and treatments | |
| GB2228413B (en) | Biocidal compositions and treatments | |
| DE69940551D1 (de) | Mercaptane und disulfide | |
| IE820976L (en) | 4'-halo-4'-deoxysucrose derivatives | |
| EP0264953A3 (en) | Amino acid preparations containing n,n'-bis-l-amino acid-l-cystin peptides for oral and parenteral use | |
| EP0237829A3 (en) | Tetrahydro-3,4-furandiamine-n-n'-platinum complexes | |
| TR199802270A2 (xx) | S�lfonamid-ikame etmi� anelize 5-halka-bile�ikleri. | |
| GB9420747D0 (en) | 1,5 benzodiazepine derivatives | |
| DE69506903D1 (de) | Erhöhte solubiliierung von komplexsalzen von methionin mit zink und mangan durch zusatz von ferriionen | |
| ATE232723T1 (de) | Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen | |
| TR199701605A2 (xx) | S�lfonamid-substit�e edilmi� bile�ikler | |
| DE3686266D1 (de) | Neue 5-fluoruridin-verbindungen und deren herstellung. | |
| ATE222103T1 (de) | Inklusionskomplexe in waessriger loesung | |
| DK418785A (da) | Vanskeligt antaendelig, biologisk nedbrydelig funktionel vaeske | |
| NO894505D0 (no) | Vandig cisplatinloesning. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0792154 Country of ref document: EP |